The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism

BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression is required for chronic lymphocytic leukemia (CLL) survival. Venetoclax (ABT-199) is a small-molecule selective inhibitor of BCL2 currently in clinical trials for CLL and other malignancies. In conjunction wi...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Anderson, Mary Ann, Deng, Jing, Seymour, John F., Tam, Constantine, Kim, Su Young, Fein, Joshua, Yu, Lijian, Brown, Jennifer R., Westerman, David, Si, Eric G., Majewski, Ian J., Segal, David, Heitner Enschede, Sari L., Huang, David C. S., Davids, Matthew S., Letai, Anthony, Roberts, Andrew W.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2016
主題:
Lymphoid Neoplasia
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4920022/
https://ncbi.nlm.nih.gov/pubmed/27069256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-01-688796
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍